

# LEVETIRACETAM

100 mg/mL  
Concentrate for Solution for IV Infusion




## 1.0 PHARMACOLOGIC CATEGORY

Antiepileptics

## 2.0 DESCRIPTION

Non-proprietary name: Levetiracetam

Chemical structure:



Molecular formula:  $C_8H_{14}N_2O_2$

CAS number: 102767-28-2

Molecular weight: 170.2

Levetiracetam concentrate for IV infusion is a clear, colorless and sterile aqueous solution containing 100 mg of levetiracetam per mL (each 5 mL vial contains 500 mg of levetiracetam).

Levetiracetam concentrate for IV infusion contains the following excipients: sodium acetate trihydrate, sodium chloride, acetic acid - glacial, water for injections and nitrogen.

## 3.0 FORMULATION/COMPOSITION

Each mL contains Levetiracetam, Ph Eur. 100 mg.

## 4.0 CLINICAL PARTICULARS

### 4.1 Therapeutic Indications

Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalization in adults and adolescents from 16 years of age with newly diagnosed epilepsy.

Levetiracetam is indicated as adjunctive therapy

- in the treatment of partial onset seizures with or without secondary generalization in adults, adolescents and children from 4 years of age with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
- in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalized Epilepsy.

Levetiracetam concentrate is an alternative for patients when oral administration is temporarily not feasible.

## **4.2 Dosage and Method of Administration**

### **Dosage and Administration**

Levetiracetam therapy can be initiated with either intravenous or oral administration.

Conversion to or from oral to intravenous administration can be done directly without titration. The total daily dose and frequency of administration should be maintained.

#### ***Partial onset seizures***

The recommended dosing for monotherapy (from 16 years of age) and adjunctive therapy is the same; as outlined below.

#### ***All indications***

#### ***Adults (≥18 years of age) and adolescents (12-17 years of age) weighing 50 kg or more***

The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. However, a lower initial dose of 250 mg twice daily may be given based on physician assessment of seizure reduction versus potential side effects. This can be increased to 500 mg twice daily after two weeks.

Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 250 mg or 500 mg twice daily increases or decreases every two to four weeks.

#### ***Adolescents (12 to 17 years) weighing below 50 kg and children from 4 years of age***

The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to weight, age and dose. Refer to Pediatric population section for dosing adjustments based on weight.

### **Duration of treatment**

There is no experience with administration of intravenous Levetiracetam for longer period than 4 days.

### **Discontinuation**

If Levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g., in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in children and adolescents weighing less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks).

### **Special populations**

#### ***Elderly (65 years and older)***

Adjustment of the dose is recommended in elderly patients with compromised renal function (see “Renal impairment” below).

#### ***Renal impairment***

The daily dose must be individualized according to renal function.

For adult patients, refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient's creatinine clearance (CL<sub>cr</sub>) in mL/min is needed. The CL<sub>cr</sub> in mL/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighing 50 kg or more, the following formula:

$$\text{CLcr (mL/min)} = \frac{[140 - \text{age (years)}] \times \text{weight (kg)}}{72 \times \text{serum creatinine (mg/dl)}} \quad (\times 0.85 \text{ for women})$$

Then CLcr is adjusted for body surface area (BSA) as follows:

$$\text{CLcr (mL/min/1.73 m}^2\text{)} = \frac{\text{CLcr (mL/min)}}{\text{BSA subject (m}^2\text{)}} \times 1.73$$

Dosing adjustment for adult and adolescent patients weighing more than 50 kg with impaired renal function:

Group	Creatinine clearance (mL/min/1.73 m <sup>2</sup> )	Dose and frequency
Normal	≥80	500 to 1,500 mg twice daily
Mild	50-79	500 to 1,000 mg twice daily
Moderate	30-49	250 to 750 mg twice daily
Severe	<30	250 to 500 mg twice daily
End-stage renal disease patients undergoing dialysis <sup>(1)</sup>		500 to 1,000 mg once daily <sup>(2)</sup>

<sup>(1)</sup> A 750 mg loading dose is recommended on the first day of treatment with Levetiracetam.

<sup>(2)</sup> Following dialysis, a 250 to 500 mg supplemental dose is recommended.

For children with renal impairment, Levetiracetam dose needs to be adjusted based on the renal function as Levetiracetam clearance is related to renal function. This recommendation is based on a study in adult renally impaired patients.

The CLcr in mL/min/1.73 m<sup>2</sup> may be estimated from serum creatinine (mg/dl) determination for young adolescents and children using the following formula (Schwartz formula):

$$\text{CLcr (mL/min/1.73 m}^2\text{)} = \frac{\text{Height (cm)} \times \text{ks}}{\text{Serum Creatinine (mg/dl)}}$$

ks= 0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in adolescent male

Dosing adjustment for children and adolescent patients weighing less than 50 kg with impaired renal function:

Group	Creatinine clearance (mL/min/1.73 m <sup>2</sup> )	Dose and frequency
		Children from 4 years and adolescents weighing less than 50 kg
Normal	≥80	10 to 30 mg/kg (0.10 to 0.30 mL/kg) twice daily
Mild	50-79	10 to 20 mg/kg (0.10 to 0.20 mL/kg) twice daily
Moderate	30-49	5 to 15 mg/kg (0.05 to 0.15 mL/kg) twice daily
Severe	<30	5 to 10 mg/kg (0.05 to 0.10 mL/kg) twice daily
End-stage renal disease patients undergoing dialysis	--	10 to 20 mg/kg (0.10 to 0.20 mL/kg) once daily <sup>(1)(2)</sup>

<sup>(1)</sup> A 15 mg/kg (0.15 mL/kg) loading dose is recommended on the first day of treatment with Levetiracetam.

<sup>(2)</sup> Following dialysis, a 5 to 10 mg/kg (0.05 to 0.10 mL/kg) supplemental dose is recommended.

### ***Hepatic impairment***

No dose adjustment is needed in patients with mild to moderate hepatic impairment.

In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency.

Therefore a 50% reduction of the daily maintenance dose is recommended when the creatinine clearance is <60 mL/min/1.73 m<sup>2</sup>.

### ***Pediatric population***

The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose.

#### ***Monotherapy***

The safety and efficacy of Levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.

No data are available.

*Adolescents (16 and 17 years of age) weighing 50 kg or more with partial onset seizures with or without secondary generalization with newly diagnosed epilepsy*

Please refer to the above section on *Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more.*

*Add-on therapy for children aged 4 to 11 years and adolescents (12 to 17 years) weighing less than 50 kg*

The initial therapeutic dose is 10 mg/kg twice daily.

Depending upon the clinical response and tolerability, the dose can be increased up to 30 mg/kg twice daily. Dose changes should not exceed increases or decreases of 10 mg/kg twice daily every two weeks. The lowest effective dose should be used for

all indications.

Dose in children 50 kg or greater is the same as in adults for all indications.

Please refer to the above section on *Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more* for all indications.

Dose recommendations for children and adolescents:

Weight	Starting dose: 10 mg/kg twice daily	Maximum dose: 30 mg/kg twice daily
15 kg <sup>(1)</sup>	150 mg twice daily	450 mg twice daily
20 kg <sup>(1)</sup>	200 mg twice daily	600 mg twice daily
25 kg	250 mg twice daily	750 mg twice daily
From 50 kg <sup>(2)</sup>	500 mg twice daily	1,500 twice daily

<sup>(1)</sup> Children 25 kg or less should preferably start the treatment with Levetiracetam 100 mg/mL oral solution.

<sup>(2)</sup> Dose in children and adolescents 50 kg or more is the same as in adults.

#### *Add-on therapy for infants and children less than 4 years*

The safety and efficacy of Levetiracetam concentrate for solution for infusion in infants and children less than 4 years have not been established.

Currently available data are described in sections **4.8 Undesirable effects**, **5.1 Pharmacodynamic properties**, and **5.2 Pharmacokinetic properties** but no recommendation on a posology can be made.

#### Method of administration

Levetiracetam concentrate is for intravenous use only and the recommended dose must be diluted in at least 100 mL of a compatible diluent and administered intravenously as a 15-minute intravenous infusion (see section **6.5 Special precautions for disposal and other handling**).

#### **4.3 Contraindications**

Hypersensitivity to Levetiracetam or other pyrrolidone derivatives or any of the excipients.

#### **4.4 Special Warnings and Precautions for Use**

##### Renal impairment

The administration of Levetiracetam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section **4.2 Dosage and Method of administration**).

##### Acute kidney injury

The use of Levetiracetam has been very rarely associated with acute kidney injury with a time to onset ranging from a few days to several months.

##### Blood cell counts

Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leukopenia,

thrombocytopenia and pancytopenia) have been described in association with Levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders (see section **4.8 Undesirable effects**).

#### Suicide

Suicide, suicide attempt, suicidal ideation and behavior have been reported in patients treated with antiepileptic agents (including Levetiracetam). A meta-analysis of randomized placebo-controlled trials of antiepileptic medicinal products has shown a small increased risk of suicidal thoughts and behavior. The mechanism of this risk is not known.

Therefore, patients should be monitored for signs of depression and/or suicidal ideation and behaviors and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behavior emerge.

#### Abnormal and aggressive behaviors

Levetiracetam may cause psychotic symptoms and behavioral abnormalities including irritability and aggressiveness. Patients treated with levetiracetam should be monitored for developing psychiatric signs suggesting important mood and/or personality changes. If such behaviors are noticed, treatment adaptation or gradual discontinuation should be considered. If discontinuation is considered, please refer to section **4.2 Dosage and Method of Administration**.

#### Worsening of seizures

As with other types of antiepileptic drugs, levetiracetam may rarely exacerbate seizure frequency or severity. This paradoxical effect was mostly reported within the first month after levetiracetam initiation or increase of the dose, and was reversible upon drug discontinuation or dose decrease. Patients should be advised to consult their physician immediately in case of aggravation of epilepsy.

#### Electrocardiogram QT interval prolongation

Rare cases of ECG QT interval prolongation have been observed during the post-marketing surveillance. Levetiracetam should be used with caution in patients with QTc-interval prolongation, in patients concomitantly treated with drugs affecting the QTc-interval, or in patients with relevant pre-existing cardiac disease or electrolyte disturbances.

#### Pediatric population

Available data in children did not suggest impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.

#### Excipients

This medicinal product contains 19 mg of sodium per vial. The maximum single dose (corresponding to 1,500 mg levetiracetam) contains 57 mg of sodium, equivalent to 2.85% of the WHO maximum recommended daily intake (RDI) of 2 g sodium for an adult. To be taken into consideration by patients on a controlled sodium diet.

This medicinal product may be diluted with sodium-containing solutions (see **section 4.2 Dosage and Method of Administration**) and this should be considered in

relation to the total sodium from all sources that will be administered to the patient.

#### **4.5 Interaction with Other Medicinal Products and Other Forms of Interaction**

##### Antiepileptic medicinal products

Pre-marketing data from clinical studies conducted in adults indicate that Levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of Levetiracetam.

As in adults, there is no evidence of clinically significant medicinal product interactions in pediatric patients receiving up to 60 mg/kg/day Levetiracetam.

A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered Levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. However, data suggested a 20% higher Levetiracetam clearance in children taking enzyme-inducing antiepileptic medicinal products. Dose adjustment is not required.

##### Probenecid

Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite, but not of Levetiracetam. Nevertheless, the concentration of this metabolite remains low.

##### Methotrexate

Concomitant administration of Levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and Levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.

##### Oral contraceptives and other pharmacokinetic interactions

Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. Levetiracetam 2,000 mg daily did not influence the pharmacokinetics of digoxin and warfarin; prothrombin times were not modified. Co-administration with digoxin, oral contraceptives and warfarin did not influence the pharmacokinetics of Levetiracetam.

##### Alcohol

No data on the interaction of Levetiracetam with alcohol are available.

#### **4.6 Fertility, Pregnancy and Lactation**

##### Women of child bearing potential

Specialist advice should be given to women who are of childbearing potential. Treatment with levetiracetam should be reviewed when a woman is planning to become pregnant. As with all antiepileptic medicines, sudden discontinuation of levetiracetam should be avoided as this may lead to breakthrough seizures that could have serious consequences for the woman and the unborn child. Monotherapy should be preferred whenever possible because therapy with multiple antiepileptic medicines

AEDs could be associated with a higher risk of congenital malformations than monotherapy, depending on the associated antiepileptics.

### Pregnancy

A large amount of post-marketing data on pregnant women exposed to Levetiracetam monotherapy (more than 1,800, among which in more than 1,500 exposure occurred during the 1<sup>st</sup> trimester) do not suggest an increase in the risk for major congenital malformations. Studies in animals have shown reproductive toxicity (see section **5.3 Preclinical safety data**). Only limited evidence is available on the neurodevelopment of children exposed to levetiracetam monotherapy in utero. However, current epidemiological studies (on about 100 children) do not suggest an increased risk of neurodevelopmental disorders or delays.

Levetiracetam can be used during pregnancy, if after careful assessment it is considered clinically needed. In such case, the lowest effective dose is recommended.

Physiological changes during pregnancy may affect Levetiracetam concentration. Decrease in Levetiracetam plasma concentrations has been observed during pregnancy. This decrease is more pronounced during the third trimester (up to 60% of baseline concentration before pregnancy). Appropriate clinical management of pregnant women treated with Levetiracetam should be ensured.

### Breast-feeding

Levetiracetam is excreted in human breast milk. Therefore, breast-feeding is not recommended. However, if Levetiracetam treatment is needed during breastfeeding, the benefit/risk of the treatment should be weighed considering the importance of breast-feeding.

### Fertility

No impact on fertility was detected in animal studies (see section **5.3 Preclinical safety data**). No clinical data are available, potential risk for human is unknown.

## **4.7 Effects on Ability to Drive and Use Machines**

Levetiracetam has minor or moderate influence on the ability to drive and use machines. Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. Therefore, caution is recommended in those patients when performing skilled tasks, e.g., driving vehicles or operating machinery. Patients are advised not to drive or use machines until it is established that their ability to perform such activities is not affected.

## **4.8 Undesirable Effects**

### Summary of the safety profile

The most frequently reported adverse reactions were nasopharyngitis, somnolence, headache, fatigue and dizziness. The adverse reaction profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with Levetiracetam. These data are supplemented with the use of Levetiracetam in corresponding open-label extension studies, as well as post-marketing experience. The safety profile of Levetiracetam is generally similar across age groups (adult and pediatric patients) and across the approved epilepsy indications. Since there was limited exposure for Levetiracetam intravenous use and



since oral and intravenous formulations are bioequivalent, the safety information of Levetiracetam intravenous will rely on Levetiracetam oral use.

Tabulated list of adverse reactions

Adverse reactions reported in clinical studies (adults, adolescents, children and infants >1 month) and from post-marketing experience are listed in the following table per System Organ Class and per frequency. Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1,000$  to  $< 1/100$ ); rare ( $\geq 1/10,000$  to  $< 1/1,000$ ) and very rare ( $< 1/10,000$ ).

<u>MedDRA SOC</u>	<u>Frequency category</u>			
	<u>Very common</u>	<u>Common</u>	<u>Uncommon</u>	<u>Rare</u>
<u>Infections and infestations</u>	Nasopharyngitis			Infection
<u>Blood and lymphatic system disorders</u>			Thrombocytopenia, leukopenia	Pancytopenia, neutropenia, agranulocytosis
<u>Immune system disorders</u>				Drug reaction with eosinophilia and systemic symptoms (DRESS), Hypersensitivity (including angioedema and anaphylaxis)
<u>Metabolism and nutrition disorders</u>		Anorexia	Weight decreased, weight increase	Hyponatremia
<u>Psychiatric disorders</u>		Depression, hostility/aggression, anxiety, insomnia, nervousness/irritability	Suicide attempt, suicidal ideation, psychotic disorder, abnormal behavior, hallucination, anger, confusional state, panic attack, affect lability/mood swings, agitation	Completed suicide, personality disorder, thinking abnormal, delirium
<u>Nervous system disorders</u>	Somnolence, headache	Convulsion, balance disorder, dizziness, lethargy, tremor	Amnesia, memory impairment, coordination abnormal/ataxia, paresthesia, disturbance in attention	Choreoathetosis, dyskinesia, hyperkinesia, gait disturbance, encephalopathy, seizures aggravated, Neuroleptic malignant

				syndrome*
<u>Eye disorders</u>			Diplopia, vision blurred	
<u>Ear and labyrinth disorders</u>		Vertigo		
<u>Cardiac disorders</u>				Electrocardiogram QT prolonged
<u>Respiratory, thoracic and mediastinal disorders</u>		Cough		
<u>Gastrointestinal disorders</u>		Abdominal pain, diarrhea, dyspepsia, vomiting, nausea		Pancreatitis
<u>Hepatobiliary disorders</u>			Liver function test abnormal	Hepatic failure, hepatitis
<u>Renal and urinary disorders</u>				Acute kidney injury
<u>Skin and subcutaneous tissue disorders</u>		Rash	Alopecia, eczema, pruritus	Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme
<u>Musculoskeletal and connective tissue disorders</u>			Muscular weakness, myalgia	Rhabdomyolysis and blood creatine phosphokinase increased*
<u>General disorders and administration site conditions</u>		Asthenia/fatigue		
<u>Injury, poisoning and procedural complications</u>			Injury	

\* Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients.

#### Description of selected adverse reactions

The risk of anorexia is higher when Levetiracetam is co-administered with topiramate.

In several cases of alopecia, recovery was observed when Levetiracetam was discontinued.

Bone marrow suppression was identified in some of the cases of pancytopenia.

Cases of encephalopathy generally occurred at the beginning of the treatment (few days to a few months) and were reversible after treatment discontinuation.

### Pediatric population

In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with Levetiracetam in placebo-controlled and open label extension studies. Sixty of these patients were treated with Levetiracetam in placebo-controlled studies. In patients aged 4-16 years, a total of 645 patients have been treated with Levetiracetam in placebo-controlled and open label extension studies. 233 of these patients were treated with Levetiracetam in placebo-controlled studies. In both these pediatric age ranges, these data are supplemented with the post-marketing experience of the use of Levetiracetam.

In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety study. No new safety concerns for levetiracetam were identified for infants less than 12 months of age with epilepsy.

The adverse reaction profile of Levetiracetam is generally similar across age groups and across the approved epilepsy indications. Safety results in pediatric patients in placebo-controlled clinical studies were consistent with the safety profile of Levetiracetam in adults except for behavioral and psychiatric adverse reactions which were more common in children than in adults. In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal behavior (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile. In infants and children aged 1 month to less than 4 years, irritability (very common, 11.7%) and coordination abnormal (common, 3.3%) were reported more frequently than in other age groups or in the overall safety profile.

A double-blind, placebo-controlled pediatric safety study with a non-inferiority design has assessed the cognitive and neuropsychological effects of Levetiracetam in children 4 to 16 years of age with partial onset seizures. It was concluded that Levetiracetam was not different (non-inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per- protocol population. Results related to behavioral and emotional functioning indicated a worsening in Levetiracetam treated patients on aggressive behavior as measured in a standardized and systematic way using a validated instrument (CBCL - Achenbach Child Behavior Checklist). However, subjects, who took Levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioral and emotional functioning; in particular measures of aggressive behavior were not worse than baseline.

## **4.9 Overdose and Treatment**

### Symptoms

Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with Levetiracetam overdoses.

### Management of overdose

There is no specific antidote for Levetiracetam. Treatment of an overdose will be

symptomatic and may include hemodialysis. The dialyzer extraction efficiency is 60% for levetiracetam and 74% for the primary metabolite.

## 5.0 PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic Properties

Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX14.

The active substance, Levetiracetam, is a pyrrolidone derivative (S-enantiomer of  $\alpha$ -ethyl-2-oxo-1-pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances.

#### Mechanism of action

The mechanism of action of Levetiracetam still remains to be fully elucidated. *In vitro* and *in vivo* experiments suggest that Levetiracetam does not alter basic cell characteristics and normal neurotransmission.

*In vitro* studies show that Levetiracetam affects intraneuronal  $Ca^{2+}$  levels by partial inhibition of N-type  $Ca^{2+}$  currents and by reducing the release of  $Ca^{2+}$  from intraneuronal stores. In addition, it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and  $\beta$ -carbolines. Furthermore, Levetiracetam has been shown in *in vitro* studies to bind to a specific site in rodent brain tissue. This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis.

Levetiracetam and related analogues show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. This finding suggests that the interaction between Levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.

#### **Pharmacodynamic effects**

Levetiracetam induces seizure protection in a broad range of animal models of partial and primary generalized seizures without having a pro-convulsant effect. The primary metabolite is inactive.

In man, an activity in both partial and generalized epilepsy conditions (epileptiform discharge/photoparoxysmal response) has confirmed the broad spectrum pharmacological profile of Levetiracetam.

#### Clinical efficacy and safety

*Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adults, adolescents and children from 4 years of age with epilepsy.*

In adults, Levetiracetam efficacy has been demonstrated in 3 double-blind, placebo-controlled studies at 1,000 mg, 2,000 mg, or 3,000 mg/day, given in 2 divided doses, with a treatment duration of up to 18 weeks. In a pooled analysis, the percentage of patients who achieved 50% or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7%, 31.6% and 41.3% for patients on 1,000, 2,000 or 3,000 mg Levetiracetam respectively and of 12.6% for patients on placebo.

### *Pediatric population*

In pediatric patients (4 to 16 years of age), Levetiracetam efficacy was established in a double-blind, placebo-controlled study, which included 198 patients and had a treatment duration of 14 weeks. In this study, the patients received Levetiracetam as a fixed dose of 60 mg/kg/day (with twice a day dosing).

44.6% of the Levetiracetam treated patients and 19.6% of the patients on placebo had a 50% or greater reduction from baseline in the partial onset seizure frequency per week. With continued long-term treatment, 11.4% of the patients were seizure-free for at least 6 months and 7.2% were seizure-free for at least 1 year.

35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged <6 months.

### *Monotherapy in the treatment of partial onset seizures with or without secondary generalization in patients from 16 years of age with newly diagnosed epilepsy.*

Efficacy of Levetiracetam as monotherapy was established in a double-blind, parallel group, noninferiority comparison to carbamazepine-controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. The patients had to present with unprovoked partial seizures or with generalized tonic-clonic seizures only. The patients were randomized to carbamazepine CR 400-1,200 mg/day or Levetiracetam 1,000-3,000 mg/day, the duration of the treatment was up to 121 weeks depending on the response.

Six-month seizure freedom was achieved in 73.0% of Levetiracetam-treated patients and 72.8% of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2% (95% CI:-7.8-8.2). More than half of the subjects remained seizure free for 12 months (56.6% and 58.5% of subjects on Levetiracetam and on carbamazepine CR respectively).

In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to Levetiracetam adjunctive therapy (36 adult patients out of 69).

### *Adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.*

Levetiracetam efficacy was established in a double-blind, placebo-controlled study of 16 weeks duration, in patients 12 years of age and older suffering from idiopathic generalized epilepsy with myoclonic seizures in different syndromes. The majority of patients presented with juvenile myoclonic epilepsy. In this study, levetiracetam, dose was 3,000 mg/day given in 2 divided doses. 58.3% of the Levetiracetam treated patients and 23.3% of the patients on placebo had at least a 50% reduction in myoclonic seizure days per week. With continued long-term treatment, 28.6% of the patients were free of myoclonic seizures for at least 6 months and 21.0% were free of myoclonic seizures for at least 1 year.

### *Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalized epilepsy.*

Levetiracetam efficacy was established in a 24-week double-blind, placebo-controlled study which included adults, adolescents and a limited number of children suffering from idiopathic generalized epilepsy with primary generalized tonic-clonic (PGTC) seizures in different syndromes (juvenile myoclonic epilepsy, juvenile absence

epilepsy, childhood absence epilepsy, or epilepsy with Grand Mal seizures on awakening). In this study, Levetiracetam dose was 3,000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses.

72.2% of the Levetiracetam treated patients and 45.2% of the patients on placebo had a 50% or greater decrease in the frequency of PGTC seizures per week. With continued long-term treatment, 47.4% of the patients were free of tonic-clonic seizures for at least 6 months and 31.5% were free of tonic-clonic seizures for at least 1 year.

## **5.2 Pharmacokinetic Properties**

The pharmacokinetic profile has been characterized following oral administration. A single dose of 1,500 mg Levetiracetam diluted in 100 mL of a compatible diluent and infused intravenously over 15 minutes is bioequivalent to 1,500 mg Levetiracetam oral intake, given as three 500 mg tablets.

The intravenous administration of doses up to 4,000 mg diluted in 100 mL of 0.9% sodium chloride infused over 15 minutes and doses up to 2,500 mg diluted in 100 mL of 0.9% sodium chloride infused over 5 minutes was evaluated. The pharmacokinetic and safety profiles did not identify any safety concerns.

Levetiracetam is a highly soluble and permeable compound. The pharmacokinetic profile is linear with low intra- and inter-subject variability. There is no modification of the clearance after repeated administration. The time independent pharmacokinetic profile of Levetiracetam was also confirmed following 1,500 mg intravenous infusion for 4 days with twice daily dosing.

There is no evidence for any relevant gender, race or circadian variability. The pharmacokinetic profile is comparable in healthy volunteers and in patients with epilepsy.

### ***Adults and Adolescents***

#### **Distribution**

Peak plasma concentration ( $C_{max}$ ) observed in 17 subjects following a single intravenous dose of 1,500 mg infused over 15 minutes was  $51 \pm 19$  micrograms/mL (arithmetic average  $\pm$  standard deviation).

No tissue distribution data are available in humans.

Neither Levetiracetam nor its primary metabolite are significantly bound to plasma proteins (<10%). The volume of distribution of Levetiracetam is approximately 0.5 to 0.7 L/kg, a value close to the total body water volume.

#### **Biotransformation**

Levetiracetam is not extensively metabolized in humans. The major metabolic pathway (24% of the dose) is an enzymatic hydrolysis of the acetamide group. Production of the primary metabolite, ucb L057, is not supported by liver cytochrome P<sub>450</sub> isoforms. Hydrolysis of the acetamide group was measurable in a large number of tissues including blood cells. The metabolite ucb L057 is pharmacologically inactive.

Two minor metabolites were also identified. One was obtained by hydroxylation of the pyrrolidone ring (1.6% of the dose) and the other one by opening of the pyrrolidone ring (0.9% of the dose). Other unidentified components accounted only for 0.6% of the dose.

No enantiomeric interconversion was evidenced *in vivo* for either Levetiracetam or its primary metabolite.

*In vitro*, Levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P<sub>450</sub> isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 and UGT1A6) and epoxide hydroxylase activities. In addition, Levetiracetam does not affect the *in vitro* glucuronidation of valproic acid.

In human hepatocytes in culture, Levetiracetam had little or no effect on CYP1A2, SULT1E1 or UGT1A1. Levetiracetam caused mild induction of CYP2B6 and CYP3A4. The *in vitro* data and *in vivo* interaction data on oral contraceptives, digoxin and warfarin indicate that no significant enzyme induction is expected *in vivo*. Therefore, the interaction of Levetiracetam with other substances, or *vice versa*, is unlikely.

### **Elimination**

The plasma half-life in adults was  $7 \pm 1$  hours and did not vary either with dose, route of administration or repeated administration. The mean total body clearance was 0.96 mL/min/kg.

The major route of excretion was via urine, accounting for a mean 95% of the dose, with approximately 93% of the dose was excreted within 48 hours. Excretion via feces accounted for only 0.3% of the dose. The cumulative urinary excretion of Levetiracetam and its primary metabolite accounted for 66% and 24% of the dose, respectively during the first 48 hours.

The renal clearance of Levetiracetam and ucb L057 is 0.6 and 4.2 mL/min/kg respectively indicating that Levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and that the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration.

Levetiracetam elimination is correlated to creatinine clearance.

#### *Elderly*

In the elderly, the half-life is increased by about 40% (10 to 11 hours). This is related to the decrease in renal function in this population (see section **4.2 Dosage and Method of Administration**).

#### *Renal impairment*

The apparent body clearance of both Levetiracetam and of its primary metabolite is correlated to the creatinine clearance. It is therefore recommended to adjust the maintenance daily dose of Levetiracetam, based on creatinine clearance in patients with moderate and severe renal impairment (see **Section 4.2 Dosage and Method of Administration**).

In anuric end-stage renal disease adult subjects the half-life was approximately 25 and 3.1 hours during interdialytic and intradialytic periods respectively.

The fractional removal of Levetiracetam was 51% during a typical 4-hour dialysis session.

#### *Hepatic impairment*

In subjects with mild and moderate hepatic impairment, there was no relevant modification of the clearance of Levetiracetam. In most subjects with severe hepatic

impairment, the clearance of Levetiracetam was reduced by more than 50% due to a concomitant renal impairment (see **Section 4.2 Dosage and Method of Administration**).

#### *Pediatric population*

##### **Children (4 to 12 years of age)**

The pharmacokinetics in pediatric patients has not been investigated after intravenous administration.

However, based on the pharmacokinetic characteristics of Levetiracetam, the pharmacokinetics in adults after intravenous administration and the pharmacokinetics in children after oral administration, the exposure (AUC) of Levetiracetam is expected to be similar in pediatric patients aged 4 to 12 years after intravenous and oral administration.

Following single oral dose administration (20 mg/kg) to epileptic children (6 to 12 years of age), the half-life of Levetiracetam was 6.0 hours. The apparent body weight adjusted clearance was approximately 30% higher than in epileptic adults.

Following repeated oral dose administration (20 to 60 mg/kg/day) to epileptic children (4 to 12 years of age), Levetiracetam was rapidly absorbed. Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. Linear and dose proportional increases were observed for peak plasma concentrations and area under the curve. The elimination half-life was approximately 5 hours. The apparent body clearance was 1.1 mL/min/kg.

### **5.3 Preclinical Safety Data**

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenic potential.

Adverse effects not observed in clinical studies but seen in the rat and to a lesser extent in the mouse at exposure levels similar to human exposure levels and with possible relevance for clinical use were liver changes, indicating an adaptive response such as increased weight and centrilobular hypertrophy, fatty infiltration and increased liver enzymes in plasma.

No adverse reactions on male or female fertility or reproduction performance were observed in rats at doses up to 1,800 mg/kg/day (x 6 the MRHD on a mg/m<sup>2</sup> or exposure basis) in parents and F1 generation.

Two embryo-fetal development (EFD) studies were performed in rats at 400, 1,200 and 3,600 mg/kg/day. At 3,600 mg/kg/day, in only one of the 2 EFD studies, there was a slight decrease in fetal weight associated with a marginal increase in skeletal variations/minor anomalies. There was no effect on embryomortality and no increased incidence of malformations. The NOAEL (No Observed Adverse Effect Level) was 3,600 mg/kg/day for pregnant female rats (x 12 the MRHD on a mg/m<sup>2</sup> basis) and 1,200 mg/kg/day for fetuses.

Four embryo-fetal development studies were performed in rabbits covering doses of 200, 600, 800, 1,200 and 1,800 mg/kg/day. The dose level of 1,800 mg/kg/day induced a marked maternal toxicity and a decrease in fetal weight associated with increased incidence of fetuses with cardiovascular/skeletal anomalies. The NOAEL was <200 mg/kg/day for the dams and 200 mg/kg/day for the fetuses (equal to the MRHD on a mg/m<sup>2</sup> basis).



A peri- and post-natal development study was performed in rats with Levetiracetam doses of 70, 350 and 1,800 mg/kg/day. The NOAEL was  $\geq 1,800$  mg/kg/day for the F0 females, and for the survival, growth and development of the F1 offspring up to weaning (x 6 the MRHD on a mg/m<sup>2</sup> basis).

Neonatal and juvenile animal studies in rats and dogs demonstrated that there were no adverse effects seen in any of the standard developmental or maturation endpoints at doses up to 1,800 mg/kg/day (x 6-17 the MRHD on a mg/m<sup>2</sup> basis)

## 6.0 PHARMACEUTICAL PARTICULARS

### 6.1 Shelf-Life

Please see outer package for the expiry date.

### 6.2 Storage Condition(s)

Store at temperatures not exceeding 30°C. Protect from light.

From a microbiological point of view, the product should be used immediately after dilution. If not used immediately, in-use storage time and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

This medicinal product does not require any special storage conditions.

### 6.3 Availability

5 mL glass vial (type I) with bromobutyl coated rubber stoppers and an aluminum flip-off seal. Box of 1's.

### 6.4 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section **6.5 Special precautions for disposal and other handling**.

### 6.5 Special precautions for disposal and other handling

See the table below for the recommended preparation and administration of Levetiracetam concentrate for solution for infusion to achieve a total daily dose of 500 mg, 1,000 mg, 2,000 mg, or 3,000 mg in two divided doses.

Preparation and administration of Levetiracetam concentrate for solution for infusion

Dose	Withdrawal Volume	Volume of Diluent	Infusion Time	Frequency of Administration	Total Daily Dose
250 mg	2.5 mL (half 5 mL vial)	100 mL	15 minutes	Twice daily	500 mg/day
500 mg	5 mL (one 5 mL vial)	100 mL	15 minutes	Twice daily	1,000 mg/day
1,000 mg	10 mL (two 5 mL vials)	100 mL	15 minutes	Twice daily	2,000 mg/day
1,500 mg	15 mL (three 5 mL vials)	100 mL	15 minutes	Twice daily	3,000 mg/day

This medicinal product is for single use only, any unused solution should be discarded.

Levetiracetam concentrate for solution for infusion was found to be physically compatible and chemically stable when mixed with the following diluents:

- Sodium chloride 9 mg/mL (0.9%) solution for injection
- Lactated Ringer's solution for injection
- Dextrose 50 mg/mL (5%) solution for injection

Medicinal product with particulate matter or discoloration should not be used.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

#### **7.0 FDA REGISTRATION NUMBER**

DR-XY 46035

#### **8.0 DATE OF FIRST AUTHORIZATION/RENEWAL OF AUTHORIZATION**

October 02, 2017

Keep out of reach of children.

**For suspected adverse drug reaction, report to the FDA: [www.fda.gov.ph](http://www.fda.gov.ph)**

**Seek medical attention immediately at the first sign of any adverse drug reaction.**

**CAUTION:** Foods, Drugs, Devices and Cosmetics Act prohibits dispensing without prescription.

#### **Manufactured by:**

Gland Pharma Limited.

Survey No. 143 - 148, 150 & 151, Near Gandimaisamma Cross Roads, D. P. Pally,  
Dundigal Post, Dundigal - Gandimaisamma Mandal, Medchal - Malkajgiri District,  
Hyderabad, Telangana 500043, India

#### **Marketing Authorization Holder:**

PFIZER, INC.

19F-20F, 8 Rockwell Building, Hidalgo Drive,  
Rockwell Center, Poblacion,  
Makati City 1210 Metro Manila,  
Philippines

Revision No: 4.1 Revision Date: 27 Aug 2024 Reference: EU CP SPC/ Manufacturer Address update (resubmit) Reference Date: 14 June 2022
---